The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Solazyme met expectations on revenues and exceeded expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped and GAAP loss per share increased.
Margins dropped across the board.
Solazyme reported revenue of $8.6 million. The 10 analysts polled by S&P Capital IQ looked for a top line of $8.6 million on the same basis. GAAP reported sales were 4.0% lower than the prior-year quarter's $8.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.32. The four earnings estimates compiled by S&P Capital IQ anticipated -$0.34 per share. GAAP EPS were -$0.37 for Q3 versus -$0.24 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 84.5%, 930 basis points worse than the prior-year quarter. Operating margin was -269.5%, 11,270 basis points worse than the prior-year quarter. Net margin was -262.2%, 10,460 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $11.1 million. On the bottom line, the average EPS estimate is -$0.33.
Next year's average estimate for revenue is $47.2 million. The average EPS estimate is -$1.16.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 335 members out of 356 rating the stock outperform, and 21 members rating it underperform. Among 68 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 58 give Solazyme a green thumbs-up, and 10 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Solazyme is outperform, with an average price target of $18.50.
Are you missing a major story in the energy space? Read about "One Stock to Own Before Nat Gas Act 2011 Becomes Law." Click here for instant access to this free report.
- Add Solazyme to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of Solazyme. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.